Heterotopic heart transplantation: where do we stand?

被引:10
|
作者
Flecher, Erwan [1 ]
Fouquet, Olivier [2 ]
Ruggieri, Vito Giovanni [1 ]
Chabanne, Celine [1 ]
Lelong, Bernard [1 ]
Leguerrier, Alain [1 ]
机构
[1] Rennes Univ Hosp, Dept Cardiothorac & Vasc Surg, Rennes, France
[2] Angers Univ Hosp, Dept Cardiac Surg, Angers, France
关键词
Heterotopic; Orthotopic; Transplantation; FIXED PULMONARY-HYPERTENSION; CIRCULATORY SUPPORT; HEMODYNAMICS; PIONEER;
D O I
10.1093/ejcts/ezt136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Orthotopic heart transplantation (OHT) is a well established and commonly utilized procedure for end-stage heart failure patients. Heterotopic heart transplantation (HHT) is a surgical procedure that allows the graft to be connected to the native heart in a parallel fashion. The main advantage of HHT is to assist the patient's native heart and to maintain circulation in the cases of severe acute rejection. HHT has also been proposed to overcome pulmonary hypertension, to increase the size of the donor pool and to decrease waiting times without increasing morbidity caused by the procedure. However, only a few papers have reported the short- or long-term results of HHT, and most of these studies have included <30 cases. OHT remains the standard technique and is preferable whenever the patient meets the current criteria and a suitable organ is available. HHT is far less useful than in the past because of the major advances in immunosuppression therapy and the development of long-term mechanical circulatory support. This study reviews the origin of HHT and discusses clinical developments, including their advantages and disadvantages.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 50 条
  • [21] Brain death and organ donation in India, where do we stand? A personal experience
    Nayak, Pralaya K.
    Mahapatra, Ashok K.
    NEUROSCIENCES, 2009, 14 (01) : 98 - 99
  • [22] Immunological Issues in Clinical Composite Tissue Allotransplantation: Where Do We Stand Today?
    Morelon, Emmanuel
    Kanitakis, Jean
    Petruzzo, Palmina
    TRANSPLANTATION, 2012, 93 (09) : 855 - 859
  • [23] Heterotopic heart transplantation: experimental development and clinical experience
    Kadner, A
    Chen, RH
    Adams, DH
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2000, 17 (04) : 474 - 481
  • [24] Heterotopic Cervical Heart Transplantation in Mice
    Ratschiller, Thomas
    Deutsch, Marcus-Andre
    Calzada-Wack, Julia
    Neff, Frauke
    Roesch, Christiane
    Guenzinger, Ralf
    Lange, Ruediger
    Krane, Markus
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2015, (102): : 1 - 7
  • [25] Patient-Specific Surgical Planning, Where Do We Stand? The Example of the Fontan Procedure
    de Zelicourt, Diane A.
    Kurtcuoglu, Vartan
    ANNALS OF BIOMEDICAL ENGINEERING, 2016, 44 (01) : 174 - 186
  • [26] Relapsed/Refractory Primary Mediastinal B-cell Lymphoma: Where do we Stand?
    Gulati, Nitya
    Giulino-Roth, Lisa
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (11): : 649 - 650
  • [27] Interferon regulatory factors: Where to stand in transplantation
    Assadiasl, Sara
    Shahi, Abbas
    Salehi, Saeedeh
    Afzali, Shima
    Amirzargar, Aliakbar
    TRANSPLANT IMMUNOLOGY, 2018, 51 : 76 - 80
  • [28] Regenerative medicine in kidney disease: where we stand and where to go
    Borges, Fernanda T.
    Schor, Nestor
    PEDIATRIC NEPHROLOGY, 2018, 33 (09) : 1457 - 1465
  • [29] Better together: a reappraisal of heterotopic heart transplantation
    Cockrell, Hannah C.
    O'Brien, Robert
    Carter, Kristen T.
    Shaw, Taylor B.
    Baran, David A.
    Kutcher, Matthew E.
    Copeland, Jack G.
    Copeland, Hannah
    TRANSPLANT INTERNATIONAL, 2021, 34 (11) : 2184 - 2191
  • [30] The total artificial heart: where have we been, where are we now, where are we going?
    Arabia, Francisco A. A.
    Murray, Catherine Friederich
    INDIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 39 (SUPPL 1) : 198 - 205